BlueCrest Capital Management’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

BlueCrest Capital Management’s Portfolio AST Stock Details AST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-36,693	Closed	-$48K	–	1758
2018 Q3	$48K	Buy	36,693 +8,724	+31%	+$13.5K	﹤0.01%	1439
2018 Q2	$38K	Buy	+27,969	New	+$42.8K	﹤0.01%	1441
2015 Q2	–	Sell	-18,410	Closed	-$124K	–	1051
2015 Q1	$124K	Buy	+18,410	New	+$91.2K	0.01%	582

Other funds holding AST

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

NFC

Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlueCrest Capital Management's AST Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q4 2018, closing a stake of 36,693 shares — an estimated $48K sold.

BlueCrest Capital Management first reported a position in AST in Q1 2015 and held it in 3 quarters. The position peaked at $124K in Q1 2015. 46 funds tracked by Wall St. Rank hold AST as of Q4 2018.

BlueCrest Capital Management reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q4 2018 after selling out during the quarter.
BlueCrest Capital Management sold 36,693 Asterias Biotherapeutics Inc. Series A shares in Q4 2018, an estimated $48K.
BlueCrest Capital Management first reported a position in Asterias Biotherapeutics Inc. Series A in Q1 2015 and held it in 3 quarters.
BlueCrest Capital Management's Asterias Biotherapeutics Inc. Series A position peaked at $124K in Q1 2015.
46 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.